Despite U.S. Federal Drug Administration regulation of the approval and use of pharmaceutical products, “off-label” marketing of drugs (for purposes other than those for which the drug was approved) has occurred in all aspects of the US health care system. In a new study, researchers report that the most common alleged off-label marketing practices also appear to be the most difficult to control through external regulatory approaches.